Phase 1 Trial of First-in-Class ADC DYP688 Shows Promising Activity in Metastatic Uveal Melanoma
Key Insights
DYP688, a first-in-class antibody-drug conjugate targeting the Gq/11 (search) pathway, demonstrated measurable anti-tumor activity in a Phase 1 trial for metastatic uveal melanoma (search) published in Nature Medicine.
The trial achieved disease control in more than 80% of patients and cancer shrinkage in nearly 20%, with an exceptionally high degree of patient tolerability.
Unlike conventional ADCs carrying broadly toxic chemotherapy, DYP688 uses a Gq/11 (search) inhibitor to selectively block the cancer's growth pathway while sparing healthy cells.
A Phase 1 clinical trial of DYP688, a first-in-class antibody-drug conjugate (ADC), has produced encouraging results in patients with metastatic uveal melanoma (search) (UM), an aggressive eye cancer with historically poor outcomes and limited treatment options. The findings, published in Nature Medicine, were announced by Northwell Health's Feinstein Institutes for Medical Research (search).
Patients with metastatic uveal melanoma (search) often face a survival rate of less than two years once the disease spreads. The cancer, which originates in the eye, most commonly metastasizes to the liver, making it exceptionally challenging to treat. UM represents a major unmet medical need, with limited effective systemic therapies available.
"This first-in-class antibody-drug conjugate is a smart, targeted therapy designed to kill only diseased cells – a novel approach that differs from conventional cytotoxic drugs," said Richard D. Carvajal, MD, deputy physician-in-chief and director of medical oncology at the Northwell Health Cancer Institute and the Roy J. and Tara Zuckerberg Professor in Medical Oncology. "In this study, we observed promising results alongside an exceptionally high degree of patient tolerability. While Novartis has made a business decision to halt its development, the academic and patient communities recognize its potential."
A Novel Mechanism of Action
DYP688 represents a departure from traditional ADC design. Unlike many ADCs that carry broadly toxic chemotherapy, killing all cells in their path, DYP688 identifies diseased cells with a Gq/11 (search) inhibitor designed to specifically block the cancer's growth pathway. This precision approach is grounded in the biology of uveal melanoma, which is almost universally driven by a specific genetic pathway called Gq/11, making it a well-defined target for specialized treatment.
Clinical Efficacy and Safety
The Phase 1 trial results showed disease control in more than 80 percent of patients and cancer shrinkage in nearly 20 percent, offering tangible hope in a disease with historically poor outcomes. Importantly, the therapy also successfully mitigated severe systemic toxicities, demonstrating an exceptionally high degree of patient tolerability.
"Precision medicine is the key to better treatment," said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. "Dr. Carvajal's leadership in completing this trial demonstrates the importance of rigorous research and will hopefully inspire future investigation into this treatment."
Future Outlook
Despite the promising clinical data, Novartis has made a business decision to halt the development of DYP688. However, the academic and patient communities continue to recognize the drug's therapeutic potential, and the published results may inspire further investigation into this targeted approach for metastatic uveal melanoma (search).